Search results
Results from the WOW.Com Content Network
Indole-3-butyric acid (1H-indole-3-butanoic acid, IBA) is a white to light-yellow crystalline solid, with the molecular formula C 12 H 13 NO 2. It melts at 125°C in atmospheric pressure and decomposes before boiling. IBA is a plant hormone in the auxin family and is an ingredient in many commercial horticultural plant rooting products.
Ibalizumab is being developed by TaiMed Biologics but was originally developed by Tanox, now part of Genentech.As part of Genentech's takeover of Tanox, the patent for ibalizumab was sold to TaiMed Biologics, a biotech company formed in 2007 with support from the Taiwanese Government through a $20 million investment by the state-owned National Development Fund.
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. [4] It may also be used to treat hypercalcemia (elevated blood calcium levels).
Ibogaine is a psychoactive indole alkaloid obtained either by extraction from plants in the family Apocynaceae such as Tabernanthe iboga, Voacanga africana, and Tabernaemontana undulata or by semi-synthesis from the precursor compound voacangine, another plant alkaloid.
IBA has developed an affinity chromatography system for non-magnetic isolation of peripheral blood mononuclear cells, T cells, B cells and other cells of interest. This technology is known as Fab-TACS (Traceless Affinity Cell Selection) and is based on Strep-tagged Fab fragments, which reversibly capture and release the target cells.
It is also possibly identical to three other proteins, Iba-2, MRF-1 (microglia response factor) and daintain. However complete functional profiles of all three proteins and how they overlap is unknown. [7] IBA1 is a 17-kDa EF hand protein that is specifically expressed in macrophages / microglia and is upregulated during the activation of these ...
Enfuvirtide works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.A biomimetic peptide, enfuvirtide was designed to mimic components of the HIV-1 fusion machinery and displace them, preventing normal fusion.
Elvitegravir (EVG) is an integrase inhibitor used to treat HIV infection. It was developed [1] by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008.